GI 6207

Drug Profile

GI 6207

Alternative Names: GI-6207; Recombinant Saccharomyces cerevisiae-CEA (610D)

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator GlobeImmune
  • Class Cancer vaccines; Yeasts
  • Mechanism of Action Carcinoembryonic antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thyroid cancer
  • Phase I Solid tumours

Most Recent Events

  • 05 Feb 2016 GI 6207 is still in phase II trials for Thyroid cancer in USA (SC)
  • 04 Aug 2015 GI 6207 licensed to Celgene Corporation worldwide
  • 03 Apr 2013 Phase-II clinical trials in Thyroid cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top